Karuna Therapeutics, Inc. (KRTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Boston, MA, United States. El CEO actual es William Meury.
KRTX tiene fecha de IPO 2019-06-28, 339 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $12.6B.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for psychiatric and neurological disorders. The company's lead product candidate, KarXT, is an oral muscarinic receptor modulator currently in Phase III clinical trials for treating acute psychosis in schizophrenia patients, as well as negative and cognitive symptoms associated with schizophrenia, psychosis, and dementia-related psychosis. Karuna has established strategic partnerships with major pharmaceutical and research organizations, including Eli Lilly and Company, Zai Lab, PureTech Health, Charles River Laboratories, and PsychoGenics, Inc. Based in Boston, Massachusetts, the company was incorporated in 2009 and rebranded as Karuna Therapeutics in 2019 to reflect its expanded therapeutic focus.
